Journal of Controlled Release, Год журнала: 2024, Номер 368, С. 372 - 396
Опубликована: Март 6, 2024
Язык: Английский
Immunity, Год журнала: 2023, Номер 56(10), С. 2188 - 2205
Опубликована: Окт. 1, 2023
The cancer-immunity cycle provides a framework to understand the series of events that generate anti-cancer immune responses. It emphasizes iterative nature response where killing tumor cells by T initiates subsequent rounds antigen presentation and cell stimulation, maintaining active immunity adapting it evolution. Any step can become rate-limiting, rendering system unable control growth. Here, we update based on remarkable progress past decade. Understanding mechanism checkpoint inhibition has evolved, as our view dendritic in sustaining anti-tumor immunity. We additionally account for role microenvironment facilitating, not just suppressing, response, discuss importance considering tumor's immunological phenotype, "immunotype". While these new insights add some complexity cycle, they also provide targets research therapeutic intervention.
Язык: Английский
Процитировано
389
Nature Reviews Clinical Oncology, Год журнала: 2023, Номер 21(1), С. 47 - 66
Опубликована: Окт. 30, 2023
Язык: Английский
Процитировано
192
Nature Medicine, Год журнала: 2024, Номер 30(2), С. 531 - 542
Опубликована: Янв. 9, 2024
Pancreatic and colorectal cancers are often KRAS mutated incurable when tumor DNA or protein persists recurs after curative intent therapy. Cancer vaccine ELI-002 2P enhances lymph node delivery immune response using amphiphile (Amph) modification of G12D G12R mutant (mKRAS) peptides (Amph-Peptides-2P) together with CpG oligonucleotide adjuvant (Amph-CpG-7909). We treated 25 patients (20 pancreatic five colorectal) who were positive for minimal residual mKRAS disease (ctDNA and/or serum antigen) locoregional treatment in a phase 1 study fixed-dose Amph-Peptides-2P ascending-dose Amph-CpG-7909; enrollment is complete patient follow-up ongoing. Primary endpoints included safety recommended 2 dose (RP2D). The secondary endpoint was biomarker (longitudinal ctDNA antigen), exploratory including immunogenicity relapse-free survival (RFS). No dose-limiting toxicities observed, the RP2D 10.0 mg Amph-CpG-7909. Direct ex vivo mKRAS-specific T cell responses observed 21 (84%; 59% both CD4
Язык: Английский
Процитировано
95
Molecular Therapy, Год журнала: 2023, Номер 31(11), С. 3146 - 3162
Опубликована: Окт. 5, 2023
Язык: Английский
Процитировано
55
Nature Medicine, Год журнала: 2024, Номер 30(8), С. 2224 - 2234
Опубликована: Июнь 3, 2024
Язык: Английский
Процитировано
44
Cellular and Molecular Immunology, Год журнала: 2024, Номер 21(10), С. 1089 - 1108
Опубликована: Авг. 12, 2024
Abstract In the past decade, chimeric antigen receptor (CAR)-T cell therapy has emerged as a promising immunotherapeutic approach for combating cancers, demonstrating remarkable efficacy in relapsed/refractory hematological malignancies both pediatric and adult patients. CAR-natural killer (CAR-NK) complements CAR-T by offering several distinct advantages. CAR-NK cells do not require HLA compatibility exhibit low safety concerns. Moreover, are conducive to “off-the-shelf” therapeutics, providing significant logistic advantages over cells. Both have shown consistent results malignancies. However, their against solid tumors remains limited due various obstacles including tumor trafficking infiltration, well an immuno-suppressive microenvironment. this review, we discuss recent advances current challenges of immunotherapies, with specific focus on application tumors. We also analyze depth drawbacks compared highlight CAR optimization. Finally, explore future perspectives these adoptive highlighting increasing contribution cutting-edge biotechnological tools shaping next generation cellular immunotherapy.
Язык: Английский
Процитировано
43
EBioMedicine, Год журнала: 2024, Номер 100, С. 104963 - 104963
Опубликована: Янв. 5, 2024
Glioblastoma (GBM) is one of the most lethal central nervous systems (CNS) tumours in adults. As supplements to standard care (SOC), various immunotherapies improve therapeutic effect other cancers. Among them, tumour vaccines can serve as complementary monotherapy or boost clinical efficacy with immunotherapies, such immune checkpoint blockade (ICB) and chimeric antigen receptor T cells (CAR-T) therapy. Previous studies GBM have suggested that few neoantigens could be targeted due low mutation burden, single-peptide vaccination had limited control monotherapy. Combining diverse antigens, including neoantigens, tumour-associated antigens (TAAs), pathogen-derived optimizing vaccine design strategy may help improvement. In this review, we discussed current platforms, evaluated potential antigenic targets, challenges, perspective opportunities for
Язык: Английский
Процитировано
33
Journal of Translational Medicine, Год журнала: 2024, Номер 22(1)
Опубликована: Апрель 29, 2024
Abstract The immune system in humans is a defense department against both exogenous and endogenous hazards, where CD8 + T cells play crucial role opposing pathological threats. Various immunotherapies based on have emerged recent decades, showing their promising results treating intractable diseases. However, the fight constantly changing evolving cancers, formation function of can be challenged by tumors that might train group accomplices to resist cell killing. As cancer therapy stepped into era immunotherapy, understanding physiological cells, studying machinery tumor escape, thereby formulating different therapeutic strategies become imperative missions for clinical translational researchers fulfill. After brief basics cell-based biology covered, this review delineates mechanisms escape discusses immunotherapy regimens with own advantages setbacks, embracing challenges perspectives near future.
Язык: Английский
Процитировано
27
Molecular Cancer, Год журнала: 2024, Номер 23(1)
Опубликована: Июнь 1, 2024
Abstract Significant advancements have been made in the application of chimeric antigen receptor (CAR)-T treatment for blood cancers during previous ten years. However, its effectiveness treating solid tumors is still lacking, necessitating exploration alternative immunotherapies that can overcome significant challenges faced by current CAR-T cells. CAR-based immunotherapy against shows promise with emergence macrophages, which possess robust phagocytic abilities, antigen-presenting functions, and ability to modify tumor microenvironment stimulate adaptive responses. This paper presents a thorough examination latest progress CAR-M therapy, covering both basic scientific studies clinical trials. study examines primary obstacles hindering realization complete potential as well strategies be employed these hurdles. With revolutionary technologies like situ genetic modification, synthetic biology techniques, biomaterial-supported gene transfer, provide wider array resources manipulating tumor-associated we suggest combining advanced methods will result creation new era therapy demonstrates improved efficacy, safety, availability. Graphical
Язык: Английский
Процитировано
22
ACS Nano, Год журнала: 2024, Номер 18(9), С. 7136 - 7147
Опубликована: Фев. 26, 2024
Tapping into the innate immune system's power, nanovaccines can induce tumor-specific responses, which is a promising strategy in cancer immunotherapy. However, traditional vaccine design, requiring simultaneous loading of antigens and adjuvants, complex poses challenges for mass production. Here, we developed tumor nanovaccine platform that integrates adjuvant functions delivery vehicle, using branched polyguanidine (PolyGu) nanovaccines. These were produced by modifying polyethylenimine (PEI) with various guanidine groups, transforming PEI's cytotoxicity activation. The PolyGu based on poly(phenyl biguanidine ) (Poly-PBG) effectively stimulated dendritic cells, promoted their maturation
Язык: Английский
Процитировано
18